Summary

Europe liver fibrosis treatment market is expected to reach USD 11.04 billion by 2032 from USD 5.06 billion in 2024, growing at a substantial CAGR of 10.3% in the forecast period of 2025 to 2032.

Market Segmentation:
Europe Liver Fibrosis Treatment Market, By Treatment Type (Medication and Surgery/Therapy), Stages ( F2, F1, F3, and F4), Indication (Non-Alcoholic Steatohepatitis (NASH), Hepatitis B & C-Induced Fibrosis, Alcoholic Liver Disease (ALD), Autoimmune Liver Diseases, Genetic Disorders, and Others), Gender(Male and Female), End User (Hospitals, Specialty Clinics, Clinics, Ambulatory and Research Centers, and Others), Distribution Channel (Direct Tender and Retail Sales), Country (Germany, U.K., France, Russia, Italy, Spain, Turkey, Poland, Belgium, Netherlands, Switzerland, Denmark, Sweden, Norway, Finland, and Rest of Europe) - Industry Trends & Forecast To 2032
Overview of Europe Liver Fibrosis Treatment Market Dynamics:

Driver

• Increasing Prevalence of Liver Diseases
Restraint

• Limited Awareness of Liver Diseases
Opportunity

• Progress in Pipeline Products for Liver Fibrosis Treatment
Market Players:

The key market players operating in the Europe liver fibrosis treatment market are listed below:

• Gilead Sciences, Inc.
• AbbVie Inc.
• Merck & Co., Inc.
• Novartis AG
• Intercept Pharmaceuticals, Inc.
• F. Hoffmann-La Roche Ltd
• Abbott
• La Renon Healthcare Pvt. Ltd.
• GENFIT SA
• Madrigal Pharmaceuticals
• Aligos Therapeutics
• Pfizer Inc.
• Enanta Pharmaceuticals, Inc.
• Bristol-Myers Squibb Company
• Vertex Pharmaceuticals Incorporated
• Takeda Pharmaceutical Company Limited
• Hepion Pharmaceuticals
• Echosens
• Galectin Therapeutics, Inc.
• Conatus Pharmaceuticals
• Tvardi Therapeutics
• Viking Therapeutics
• Calliditas Therapeutics AB
• Novomedix
• Galecto Biotech
• Pilant Therapeutics, Inc.
• Sagimet Biosciences
• Gyre Therapeutics, Inc.
• Akero Therapeutics, Inc.
• CureVac SE
• Novo Nordisk A/S
• Ipsen Pharma
• AdAlta Limited
• Alentis Therapeutics AG

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1 INTRODUCTION 130
1.1 OBJECTIVES OF THE STUDY 130
1.2 MARKET DEFINITION 130
1.3 OVERVIEW OF THE EUROPE LIVER FIBROSIS TREATMENT MARKET 130
1.4 CURRENCY AND PRICING 132
1.5 LIMITATIONS 132
1.6 MARKETS COVERED 133
2 MARKET SEGMENTATION 137
2.1 MARKETS COVERED 137
2.2 GEOGRAPHICAL SCOPE 138
2.3 YEARS CONSIDERED FOR THE STUDY 139
2.4 DBMR TRIPOD DATA VALIDATION MODEL 140
2.5 MULTIVARIATE MODELLING 143
2.6 TREATMENT TYPE LIFELINE CURVE 144
2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 145
2.8 DBMR MARKET POSITION GRID 146
2.9 MARKET END USER COVERAGE GRID 147
2.10 VENDOR SHARE ANALYSIS 148
2.11 SECONDARY SOURCES 149
2.12 ASSUMPTIONS 149
3 EXECUTIVE SUMMARY 150
4 PREMIUM INSIGHTS 153
4.1 PESTAL ANALYSIS 157
4.2 PORTERS FIVE FORCES ANALYSIS 158
4.2.1 LIVER TRANSPLANTATION VOLUME AND THEIR COST FOR LIVER FIBROSIS BY COUNTRY 159
4.2.2 ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES FOR LIVER FIBROSIS: VOLUME AND COST BY COUNTRY 160
4.2.3 PARTIAL HEPATECTOMY (LIVER RESECTION) COST BY COUNTRY 162
4.2.4 CELL-BASED THERAPY COST FOR LIVER FIBROSIS TREATMENT BY COUNTRY 163
4.3 EPIDEMIOLOGY 165
4.3.1 INCIDENCE OF ALL BY GENDER 165
4.3.2 TREATMENT RATE 165
4.3.3 TREATMENT RATE 166
4.3.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL 166
4.3.5 PATIENT TREATMENT SUCCESS RATES 167
4.4 MARKETED DRUG ANALYSIS 168
4.5 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES 173
4.5.1 PATIENT FLOW DIAGRAM 173
4.5.2 KEY PRICING STRATEGIES 174
4.5.3 KEY PATIENT ENROLLMENT STRATEGIES 176
5 EUROPE LIVER FIBROSIS TREATMENT MARKET: REGULATIONS 178
6 MARKET OVERVIEW 181
6.1 DRIVERS 183
6.1.1 INCREASING PREVALENCE OF LIVER DISEASES 183
6.1.2 RISING CONSUMPTION OF ALCOHOL 183
6.1.3 RISING LIVER TRANSPLANTATION RATES 184
6.1.4 GROWING INCIDENCE OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) & NASH 185
6.2 RESTRAINTS 186
6.2.1 LIMITED AWARENESS OF LIVER DISEASES 186
6.2.2 REGULATORY CHALLENGES 186
6.3 OPPORTUNITIES 188
6.3.1 EMERGING TECHNOLOGIES AND ADVANCED TREATMENTS IN LIVER FIBROSIS MANAGEMENT 188
6.3.2 PROGRESS IN PIPELINE PRODUCTS FOR LIVER FIBROSIS TREATMENT 188
6.3.3 STRATEGIC MERGERS AND ACQUISITIONS AMONG THE KEY PLAYERS 189
6.4 CHALLENGES 191
6.4.1 LACK OF EFFECTIVE AND APPROVED ANTI-FIBROTIC DRUGS 191
6.4.2 HIGH COST OF TREATMENTS IN LIVER FIBROSIS CARE 191
7 EUROPE LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE 193
7.1 OVERVIEW 194
7.2 MEDICATION 197
7.2.1 ANTIVIRAL AGENTS 199
7.2.1.1 VELPATASVIR/SOFOSBUVIR 199
7.2.1.2 TENOFOVIR 199
7.2.1.3 LEDIPASVIR/SOFOSBUVIR 199
7.2.1.4 SOFOSBUVIR 199
7.2.1.5 ENTECAVIR 199
7.2.2 ANTIFIBROTIC AGENTS 201
7.2.2.1 OBETICHOLIC ACID 201
7.2.2.2 TGF-Β INHIBITORS 201
7.2.2.3 CONNECTIVE TISSUE GROWTH FACTOR (CTGF) INHIBITORS 201
7.2.2.4 LYSYL OXIDASE-LIKE 2 (LOXL2) INHIBITORS 201
7.2.2.5 OTHERS 201
7.2.3 ANTI-INFLAMMATORY DRUGS 203
7.2.3.1 CORTICOSTEROIDS 203
7.2.3.1.1 PREDNISONE 203
7.2.3.1.2 DEXAMETHASONE 203
7.2.3.2 TUMOR NECROSIS FACTOR (TNF) INHIBITORS 204
7.2.3.2.1 INFLIXIMAB 204
7.2.3.2.2 ETANERCEPT 204
7.2.3.3 INTERLEUKIN (IL) INHIBITORS 205
7.2.3.3.1 IL-6 INHIBITORS (TOCILIZUMAB) 205
7.2.3.3.2 IL-1 INHIBITORS (ANAKINRA) 205
7.2.4 IMMUNOSUPPRESSANTS 207
7.2.4.1 MYCOPHENOLATE MOFETIL 207
7.2.4.2 TACROLIMUS 207
7.2.4.3 CYCLOSPORINE 207
7.2.5 MARKETED DRUGS 208
7.2.5.1 VELPATASVIR/SOFOSBUVIR 208
7.2.5.2 TENOFOVIR 208
7.2.5.3 LEDIPASVIR/SOFOSBUVIR 208
7.2.5.4 OBETICHOLIC ACID (OCA) 209
7.2.5.5 SOFOSBUVIR 209
7.2.5.6 PIRFENIDONE 209
7.2.5.7 OTHERS 209
7.2.6 PIPELINE DRUGS 209
7.2.7 BRANDED DRUGS 210
7.2.7.1 EPCLUSA 210
7.2.7.2 VIREAD AND VEMLIDY 210
7.2.7.3 OCALIVA 210
7.2.7.4 HARVONI 211
7.2.7.5 SOVALDI 211
7.2.7.6 BARACLUDE 211
7.2.7.7 ACTOS 211
7.2.7.8 OTHERS 211
7.2.8 GENERIC DRUGS 211
7.2.9 ORAL 211
7.2.10 PARENTERAL 211
7.2.11 OTHERS 211
7.3 SURGERY/THERAPY 212
7.3.1 LIVER TRANSPLANTATION 213
7.3.2 ORTHOTOPIC LIVER TRANSPLANT (OLT) 213
7.3.3 LIVING DONOR LIVER TRANSPLANT (LDLT) 213
7.3.4 SPLIT LIVER TRANSPLANTATION 213
7.3.5 DOMINO LIVER TRANSPLANT 213
7.3.6 ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES 214
7.3.6.1 ENDOSCOPIC VARICEAL LIGATION (EVL) 214
7.3.6.2 TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) 214
7.3.6.3 LIVER ABLATION PROCEDURES 214
7.3.6.3.1 RADIOFREQUENCY ABLATION (RFA) 214
7.3.6.3.2 MICROWAVE ABLATION (MWA) 214
7.3.7 PARTIAL HEPATECTOMY (LIVER RESECTION) 215
7.3.7.1 SEGMENTAL RESECTION 215
7.3.7.2 LOBECTOMY 215
7.3.7.3 WEDGE RESECTION 215
7.3.8 CELL-BASED THERAPY 216
7.3.8.1 STEM CELL THERAPY 216
7.3.8.1.1 MESENCHYMAL STEM CELLS (MSCS) 216
7.3.8.1.2 HEMATOPOIETIC STEM CELLS (HSCS) 216
7.3.8.2 GENE THERAPY 217
7.3.8.2.1 CRISPR-BASED LIVER REGENERATION 217
7.3.8.2.2 HEPATIC STELLATE CELL (HSC) INHIBITORS 217
7.3.8.2.3 SIRNA-BASED THERAPIES 217
7.3.8.2.4 HEPATOCYTE APOPTOSIS INHIBITORS 217
7.3.8.2.4.1 OXIDATIVE STRESS INHIBITORS 218
7.3.8.2.4.2 EMRICASAN 218
7.3.8.2.4.3 PENTOXIFYLLINE 218
7.3.8.2.4.4 LOSARTAN 218
7.3.8.2.4.5 METHYL FERULIC ACID 218
7.3.8.2.4.6 OTHERS 218
7.4 OTHERS 218
8 EUROPE LIVER FIBROSIS TREATMENT MARKET, BY STAGES 219
8.1 OVERVIEW 220
8.2 F2 223
8.3 F1 224
8.4 F3 224
8.5 F4 225
9 EUROPE LIVER FIBROSIS TREATMENT MARKET, BY INDICATION 226
9.1 OVERVIEW 227
9.2 NON-ALCOHOLIC STEATOHEPATITIS (NASH) 230
9.3 HEPATITIS B & C-INDUCED FIBROSIS 231
9.3.1 CHRONIC HEPATITIS B VIRUS (HBV) FIBROSIS 231
9.3.2 CHRONIC HEPATITIS C VIRUS (HCV) FIBROSIS 231
9.4 ALCOHOLIC LIVER DISEASE (ALD) 232
9.5 AUTOIMMUNE LIVER DISEASES 233
9.5.1 AUTOIMMUNE HEPATITIS (AIH) 234
9.5.2 PRIMARY BILIARY CHOLANGITIS (PBC) 234
9.5.3 PRIMARY SCLEROSING CHOLANGITIS (PSC) 234
9.6 GENETIC DISORDERS 234
9.6.1 HEMOCHROMATOSIS 235
9.6.2 WILSON’S DISEASE 235
9.6.3 ALPHA-1 ANTITRYPSIN DEFICIENCY 235
9.7 OTHERS 235
10 EUROPE LIVER FIBROSIS TREATMENT MARKET, BY GENDER 236
10.1 OVERVIEW 237
10.2 MALE 240
10.2.1 40-55 YEARS 241
10.2.2 ABOVE 55 YEARS 241
10.2.3 BELOW 40 YEARS 241
10.3 FEMALE 242
10.3.1 ABOVE 55 YEARS 242
10.3.2 40-55 YEARS 242
10.3.3 BELOW 40 YEARS 242
11 EUROPE LIVER FIBROSIS TREATMENT MARKET, BY END USER 243
11.1 OVERVIEW 244
11.2 HOSPITALS 247
11.2.1 PUBLIC HOSPITALS 248
11.2.2 PRIVATE HOSPITALS 248
11.3 SPECIALTY CLINICS 248
11.3.1 HEPATOLOGY CLINICS 249
11.3.2 GASTROENTEROLOGY CLINICS 249
11.4 CLINICS 249
11.5 AMBULATORY AND RESEARCH CENTERS 250
11.6 OTHERS 251
12 EUROPE LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL 252
12.1 OVERVIEW 253
12.2 DIRECT TENDER 256
12.2.1 RETAIL SALES 257
12.2.1.1 HOSPITAL PHARMACY 257
12.2.1.2 RETAIL PHARMACY 257
12.2.1.3 ONLINE PHARMACY 257
13 EUROPE LIVER FIBROSIS TREATMENT MARKET, BY REGION 258
13.1 EUROPE 261
13.1.1 GERMANY 281
13.1.2 FRANCE 300
13.1.3 U.K. 318
13.1.4 ITALY 336
13.1.5 SPAIN 354
13.1.6 SWITZERLAND 372
13.1.7 RUSSIA 390
13.1.8 BELGIUM 407
13.1.9 NETHERLANDS 424
13.1.10 TURKEY 442
13.1.11 POLAND 458
13.1.12 SWEDEN 474
13.1.13 NORWAY 490
13.1.14 DENMARK 506
13.1.15 FINLAND 522
13.1.16 REST OF EUROPE 538
14 EUROPE LIVER FIBROSIS TREATMENT MARKET: COMPANY LANDSCAPE 539
14.1 COMPANY SHARE ANALYSIS: GLOBAL 539
15 SWOT ANALYSIS 540
16 COMPANY PROFILES 541
16.1 GILEAD SCIENCES, INC. 541
16.1.1 COMPANY SNAPSHOT 541
16.1.2 REVENUE ANALYSIS 542
16.1.3 COMPANY SHARE ANALYSIS 542
16.1.4 PRODUCT PORTFOLIO 543
16.1.5 RECENT DEVELOPMENT/NEWS 547
16.2 ABBVIE, INC. 549
16.2.1 COMPANY SNAPSHOT 549
16.2.2 REVENUE ANALYSIS 549
16.2.3 COMPANY SHARE ANALYSIS 550
16.2.4 PRODUCT PORTFOLIO 550
16.2.5 RECENT DEVELOPMENT 550
16.3 MERCK & CO, INC. 551
16.3.1 COMPANY SNAPSHOT 551
16.3.2 REVENUE ANALYSIS 552
16.3.3 COMPANY SHARE ANALYSIS 552
16.3.4 PRODUCT PORTFOLIO 552
16.3.5 RECENT DEVELOPMENT 552
16.4 NOVARTIS AG 553
16.4.1 COMPANY SNAPSHOTS 553
16.4.2 REVENUE ANALYSIS AND SEGMENTED ANALYSIS 554
16.4.3 COMPANY SHARE ANALYSIS 554
16.4.4 PRODUCT PORTFOLIO 554
16.4.5 PIPELINE PRODUCT PORTFOLIO 555
16.4.6 RECENT DEVELOPMENT 555
16.5 INTERCEPT PHARMACEUTICALS, INC. 556
16.5.1 COMPANY SNAPSHOTS 556
16.5.2 COMPANY SHARE ANALYSIS 556
16.5.3 REVENUE ANALYSIS AND SEGMENTED ANALYSIS 556
16.5.4 PRODUCT PORTFOLIO 557
16.5.5 PIPELINE PRODUCT PORTFOLIO 557
16.5.6 RECENT NEWS 558
16.6 ABBOTT 559
16.6.1 COMPANY SNAPSHOT 559
16.6.2 REVENUE ANALYSIS 559
16.6.3 PRODUCT PORTFOLIO 560
16.6.4 1.1.5 RECENT DEVELOPMENT 560
16.7 ALIGOS THERAPEUTICS 561
16.7.1 COMPANY SNAPSHOT 561
16.7.2 REVENUE ANALYSIS 561
16.7.3 PRODUCT PORTFOLIO 562
16.7.4 RECENT DEVELOPMENT 562
16.8 ALNICHE LIFE SCIENCES PVT. LTD. 564
16.8.1 COMPANY SNAPSHOT 564
16.8.2 PRODUCT PORTFOLIO 564
16.8.3 RECENT DEVELOPMENT 565
16.9 ALENTIS THERAPEUTICS AG 566
16.9.1 COMPANY SNAPSHOT 566
16.9.2 PIPELINE PRODUCT PORTFOLIO 566
16.9.3 RECENT DEVELOPMENT 566
16.10 ADALTA LIMITED 567
16.10.1 COMPANY SNAPSHOT 567
16.10.2 REVENUE ANALYSIS 567
16.10.3 PIPELINE PRODUCT PORTFOLIO 568
16.10.4 RECENT NEWS 568
16.11 AKERO THERAPEUTICS, INC. 569
16.11.1 COMPANY SNAPSHOT 569
16.11.2 REVENUE ANALYSIS 569
16.11.3 PIPELINE PRODUCT PORTFOLIO 569
16.11.4 RECENT DEVELOPMENT 570
16.12 BRISTOL-MYERS SQUIBB 571
16.12.1 COMPANY SNAPSHOT 571
16.12.2 REVENUE ANALYSIS 571
16.12.3 PRODUCT PORTFOLIO 572
16.12.4 RECENT DEVELOPMENT 572
16.13 CALLIDITAS THERAPEUTICS AB 573
16.13.1 COMPANY SNAPSHOT 573
16.13.2 PIPELINE PRODUCT PORTFOLIO 573
16.13.3 RECENT DEVELOPMENT 574
16.14 CUREVAC SE 575
16.14.1 COMPANY SNAPSHOT 575
16.14.2 REVENUE ANALYSIS 575
16.14.3 PRODUCT PORTFOLIO 576
16.14.4 RECENT DEVELOPMENT 576
16.15 CONATUSPHARMA 577
16.15.1 COMPANY SNAPSHOT 577
16.15.2 PRODUCT PORTFOLIO 577
16.15.3 RECENT DEVELOPMENT/NEWS 577
16.16 ENANTA PHARMACEUTICALS, INC. 578
16.16.1 COMPANY SNAPSHOT 578
16.16.2 REVENUE ANALYSIS 578
16.16.3 PRODUCT PORTFOLIO 579
16.16.4 RECENT DEVELOPMENT 579
16.17 ECHOSENS 580
16.17.1 COMPANY SNAPSHOT 580
16.17.2 PRODUCT PORTFOLIO 580
16.17.3 RECENT DEVELOPMENT/NEWS 581
16.18 F. HOFFMANN-LA ROCHE LTD 583
16.18.1 COMPANY SNAPSHOT 583
16.18.2 REVENUE ANALYSIS 583
16.18.3 COMPANY SHARE ANALYSIS 584
16.18.4 PRODUCT PORTFOLIO 584
16.18.5 RECENT DEVELOPMENT 584
16.19 GALECTO BIOTECH 585
16.19.1 COMPANY SNAPSHOT 585
16.19.2 REVENUE ANALYSIS 585
16.19.3 PIPELINE PRODUCT PORTFOLIO 585
16.19.4 RECENT DEVELOPMENT/NEWS 585
16.20 GALECTIN THERAPEUTICS, INC. 587
16.20.1 COMPANY SNAPSHOTS 587
16.20.2 REVENUE ANALYSIS AND SEGMENTAL ANALYSIS 587
16.20.3 PIPELINE PRODUCT PORTFOLIO 587
16.20.4 RECENT DEVELOPMENT 588
16.21 GYRE THERAPEUTICS, INC. 590
16.21.1 COMPANY SNAPSHOT 590
16.21.2 REVENUE ANALYSIS AND SEGMENTED ANALYSIS 591
16.21.3 PRODUCT PORTFOLIO 591
16.21.4 RECENT DEVELOPMENT/NEWS 592
16.22 GENFIT SA 593
16.22.1 COMPANY SNAPSHOTS 593
16.22.2 REVENUE ANALYSIS AND SEGMENTED ANALYSIS 593
16.22.3 PIPELINE PRODUCT PORTFOLIO 594
16.22.4 RECENT DEVELOPMENT 594
16.23 HEPION PHARMACEUTICALS 596
16.23.1 COMPANY SNAPSHOT 596
16.23.2 REVENUE ANALYSIS 596
16.23.3 PIPELINE PORTFOLIO 596
16.23.4 RECENT DEVELOPMENT 596
16.24 IPSEN PHARMA 598
16.24.1 COMPANY SNAPSHOT 598
16.24.2 REVENUE ANALYSIS 598
16.24.3 PIPELINE PRODUCT PORTFOLIO 599
16.24.4 RECENT NEWS/DEVELOPMENTS 599
16.25 LA RENON HEALTHCARE PVT. LTD. 601
16.25.1 COMPANY SNAPSHOT 601
16.25.2 PRODUCT PORTFOLIO 601
16.25.3 RECENT DEVELOPMENT 603
16.26 MADRIGAL PHARMACEUTICALS 604
16.26.1 COMPANY SNAPSHOTS 604
16.26.2 REVENUE ANALYSIS AND SEGMENTED ANALYSIS 604
16.26.3 PRODUCT PORTFOLIO 604
16.26.4 RECENT DEVELOPMENT 605
16.27 NOVO NORDISK A/S 606
16.27.1 COMPANY SNAPSHOT 606
16.27.2 REVENUE ANALYSIS 606
16.27.3 PIPELINE PRODUCT PORTFOLIO 607
16.27.4 RECENT DEVELOPMENT 607
16.28 NOVOMEDIX 608
16.28.1 COMPANY SNAPSHOT 608
16.28.2 PIPELINE PRODUCT PORTFOLIO 608
16.28.3 RECENT DEVELOPMENT 608
16.29 PILANT THERAPEUTICS, INC. 609
16.29.1 COMPANY SNAPSHOT 609
16.29.2 REVENUE ANALYSIS 609
16.29.3 PIPELINE PRODUCT PORTFOLIO 610
16.29.4 RECENT NEWS 610
16.30 PFIZER INC. 611
16.30.1 COMPANY SNAPSHOT 611
16.30.2 REVENUE ANALYSIS 611
16.30.3 PIPELINE PRODUCT PORTFOLIO 612
16.30.4 RECENT DEVELOPMENT/NEWS 612
16.31 SAGIMET BIOSCIENCES 613
16.31.1 COMPANY SNAPSHOTS 613
16.31.2 REVENUE ANALYSIS 613
16.31.3 1.1.4 PRODUCT PORTFOLIO 613
16.31.4 RECENT DEVELOPMENT/NEWS 614
16.32 TAKEDA PHARMACEUTICAL COMPANY LIMITED 615
16.32.1 COMPANY SNAPSHOT 615
16.32.2 REVENUE ANALYSIS 616
16.32.3 PIPELINE PRODUCT PORTFOLIO 616
16.32.4 PRODUCT PORTFOLIO 617
16.32.5 RECENT DEVELOPMENT 618
16.33 TVARDI THERAPEUTICS 619
16.33.1 COMPANY SNAPSHOT 619
16.33.2 PIPELINE PRODUCT PORTFOLIO 619
16.33.3 RECENT DEVELOPMENT/NEWS 620
16.34 VERTEX PHARMACEUTICALS INCORPORATED 621
16.34.1 COMPANY SNAPSHOT 621
16.34.2 REVENUE ANALYSIS 621
16.34.3 PRODUCT PORTFOLIO 622
16.34.4 RECENT DEVELOPMENT 623
16.35 VIKING THERAPEUTICS 625
16.35.1 COMPANY SNAPSHOT 625
16.35.2 REVENUE ANALYSIS 625
16.35.3 PIPELINE PRODUCT PORTFOLIO 625
16.35.4 RECENT DEVELOPMENT 626
17 QUESTIONNAIRE 627
18 RELATED REPORTS